
Adjuvant Pembrolizumab (NSCLC), Elacestrant, & Pirtobrutinib
OncoPharm
00:00
Landscape of Targeted Adjuvant Therapy in NSCLC
John situates current adjuvant targeted and immunotherapy options in NSCLC and anticipates future evolution.
Play episode from 07:59
Transcript


